Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 10, 2001, Pages 2722-2730

  Burstein, Harold J ^b   Kuter, Irene ^b   Campos, Susana M ^b   Gelman, Rebecca S ^b   Tribou, Laura ^b   Parker, Leroy M ^b   Manola, Judith ^b   Younger, Jerry ^b   Matulonis, Ursula ^b   Bunnell, Craig A ^b   Partridge, Ann H ^b   Richardson, Paul G ^b   Clarke, Kathryn ^b   Shulman, Lawrence N ^b   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; NAVELBINE; ONCOPROTEIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENE OVEREXPRESSION; HUMAN; METASTASIS; NEUROTOXICITY; NEUTROPENIA; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035873822     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.10.2722     Document Type: Article

References (31)

1. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808, 1998
2. Mass RD, Sanders C, Charlene K, et al: Concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 19:75a, 2000 (abstr 291)
3. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of Herceptin (tratuzumab, humanized anti-HER2 antibody) as a single agent in first-line treatment of HER2 over-expressing metastatic breast cancer (HER2+/MBC). Breast Cancer Res Treat 50:232, 1998 (abstr 21)
4. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
5. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
6. Pietras RJ, Pegram MD, Finn RS, et al: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DMA-reactive drugs. Oncogene 17:2235-2249, 1998
7. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377)
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
9. Hudis C, Seidman A, Paton V, et al: Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials. Breast Cancer Res Treat 50:232, 1998 (abstr 24)
10. Konecny G, Pegram MD, Beryt M, et al: Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 57:114, 1999 (abstr 467)
11. Soriano A, Helfrich B, Holden S, et al: Synergistic effects of chemotherapy (CT) and radiation (RT) and Herceptin against human non-small cell lung cancer (NSCLC) expressing the HER-2/neu receptor. 12th International Conference on Monoclonal Antibodies for Cancer, San Diego CA, October 14-16, 1999 (abstr 40)
12. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
13. Canobbio L, Boccardo F, Pastorino G, et al: Phase II study of Navelbine in advanced breast cancer. Semin Oncol 16:33-36, 1989 (suppl 4)
14. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
15. Romero A, Rabinovich MG, Vallejo CT, et al: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336-341, 1994
16. Degardin M, Bonneterre J, Hecquet B, et al: Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423-426, 1994
17. Twelves CJ, Dobbs NA, Curnow A, et al: A phase II multicentre UK study of vinorelbine in advanced breast cancer. Br J Cancer 70:990-993, 1994
18. Gasparini G, Caffo O, Barni S, et al: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 12:2094-2101, 1994
19. Garcia-Conde J, Lluch A, Martin M, et al: Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5:854-857, 1994
20. Barni S, Adrizzoia A, Bernard G, et al: Vinorelbine as single agent in pretreated patients with advanced breast cancer. Tumori 80:280-282, 1994
21. Weber BL, Vogel C, Jones S, et al: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730, 1995
22. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567-2574, 1995
23. Ibrahim NK, Rahman Z, Valero V, et al: Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86:1251-1257, 1999
24. Vogel C, O'Rourke M, Winer E, et al: Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10:397-402, 1999
25. Jacobs TW, Gown AM, Yaziji H, et al: Specificity of Hercept-Test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17:1983-1987, 1999
26. Hyrniuk WM, Goodyear M: The calculation of received dose intensity. J Clin Oncol 8:1935-1937, 1990
27. Miller AB, Hogestraeten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
28. Burstein HJ, Kuter I, Richardson PG, et al: Herceptin and vinorelbine for HER2-positive metastatic breast cancer: A phase II study. Proc Am Soc Clin Oncol 19:102a, 2000 (abstr 392)
29. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
30. Seidman AD, Fornier M, Esteva F, et al: Final report: Weekly (W) Herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): Analysis of efficacy by HER2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescent in situ hybridization (FISH)]. Proc Am Soc Clin Oncol 19:83a, 2000 (abstr 319)
31. Nabholtz JM, Crown J, Yonemoto L, et al: Results of two open-label multicentre pilot phase II trials with Herceptin in combination with docetaxel and platinum salts (cis- or carboplatin) (TCH) as therapy for advanced breast cancer in women overexpressing HER2. Breast Cancer Res Treat 64:82, 2000 (abstr 327)